Cargando…

Autologous Mesenchymal Stem Cells in Chronic Stroke

BACKGROUND: Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early stage of development with promises to restore function in chronic diseases. Mesenchymal stem cell (MSC) transplantation in stroke patients has shown significant improvement by reducing clinical and func...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhasin, Ashu, Srivastava, M.V. Padma, Kumaran, S. Senthil, Mohanty, Sujata, Bhatia, Rohit, Bose, Sushmita, Gaikwad, Shailesh, Garg, Ajay, Airan, Balram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343764/
https://www.ncbi.nlm.nih.gov/pubmed/22566987
http://dx.doi.org/10.1159/000333381
_version_ 1782231840934854656
author Bhasin, Ashu
Srivastava, M.V. Padma
Kumaran, S. Senthil
Mohanty, Sujata
Bhatia, Rohit
Bose, Sushmita
Gaikwad, Shailesh
Garg, Ajay
Airan, Balram
author_facet Bhasin, Ashu
Srivastava, M.V. Padma
Kumaran, S. Senthil
Mohanty, Sujata
Bhatia, Rohit
Bose, Sushmita
Gaikwad, Shailesh
Garg, Ajay
Airan, Balram
author_sort Bhasin, Ashu
collection PubMed
description BACKGROUND: Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early stage of development with promises to restore function in chronic diseases. Mesenchymal stem cell (MSC) transplantation in stroke patients has shown significant improvement by reducing clinical and functional deficits. They are feasible and multipotent and have homing characteristics. This study evaluates the safety, feasibility and efficacy of autologous MSC transplantation in patients with chronic stroke using clinical scores and functional imaging (blood oxygen level-dependent and diffusion tensor imaging techniques). METHODS: Twelve chronic stroke patients were recruited; inclusion criteria were stroke lasting 3 months to 1 year, motor strength of hand muscles of at least 2, and NIHSS of 4–15, and patients had to be conscious and able to comprehend. Fugl Meyer (FM), modified Barthel index (mBI), MRC, Ashworth tone grade scale scores and functional imaging scans were assessed at baseline, and after 8 and 24 weeks. Bone marrow was aspirated under aseptic conditions and expansion of MSC took 3 weeks with animal serum-free media (Stem Pro SFM). Six patients were administered a mean of 50–60 × 10(6) cells i.v. followed by 8 weeks of physiotherapy. Six patients served as controls. This was a non-randomized experimental controlled trial. RESULTS: Clinical and radiological scanning was normal for the stem cell group patients. There was no mortality or cell-related adverse reaction. The laboratory tests on days 1, 3, 5 and 7 were also normal in the MSC group till the last follow-up. The FM and mBI showed a modest increase in the stem cell group compared to controls. There was an increased number of cluster activation of Brodmann areas BA 4 and BA 6 after stem cell infusion compared to controls, indicating neural plasticity. CONCLUSION: MSC therapy aiming to restore function in stroke is safe and feasible. Further randomized controlled trials are needed to evaluate its efficacy.
format Online
Article
Text
id pubmed-3343764
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-33437642012-05-07 Autologous Mesenchymal Stem Cells in Chronic Stroke Bhasin, Ashu Srivastava, M.V. Padma Kumaran, S. Senthil Mohanty, Sujata Bhatia, Rohit Bose, Sushmita Gaikwad, Shailesh Garg, Ajay Airan, Balram Cerebrovasc Dis Extra Original Paper BACKGROUND: Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early stage of development with promises to restore function in chronic diseases. Mesenchymal stem cell (MSC) transplantation in stroke patients has shown significant improvement by reducing clinical and functional deficits. They are feasible and multipotent and have homing characteristics. This study evaluates the safety, feasibility and efficacy of autologous MSC transplantation in patients with chronic stroke using clinical scores and functional imaging (blood oxygen level-dependent and diffusion tensor imaging techniques). METHODS: Twelve chronic stroke patients were recruited; inclusion criteria were stroke lasting 3 months to 1 year, motor strength of hand muscles of at least 2, and NIHSS of 4–15, and patients had to be conscious and able to comprehend. Fugl Meyer (FM), modified Barthel index (mBI), MRC, Ashworth tone grade scale scores and functional imaging scans were assessed at baseline, and after 8 and 24 weeks. Bone marrow was aspirated under aseptic conditions and expansion of MSC took 3 weeks with animal serum-free media (Stem Pro SFM). Six patients were administered a mean of 50–60 × 10(6) cells i.v. followed by 8 weeks of physiotherapy. Six patients served as controls. This was a non-randomized experimental controlled trial. RESULTS: Clinical and radiological scanning was normal for the stem cell group patients. There was no mortality or cell-related adverse reaction. The laboratory tests on days 1, 3, 5 and 7 were also normal in the MSC group till the last follow-up. The FM and mBI showed a modest increase in the stem cell group compared to controls. There was an increased number of cluster activation of Brodmann areas BA 4 and BA 6 after stem cell infusion compared to controls, indicating neural plasticity. CONCLUSION: MSC therapy aiming to restore function in stroke is safe and feasible. Further randomized controlled trials are needed to evaluate its efficacy. S. Karger AG 2011-12-03 /pmc/articles/PMC3343764/ /pubmed/22566987 http://dx.doi.org/10.1159/000333381 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Original Paper
Bhasin, Ashu
Srivastava, M.V. Padma
Kumaran, S. Senthil
Mohanty, Sujata
Bhatia, Rohit
Bose, Sushmita
Gaikwad, Shailesh
Garg, Ajay
Airan, Balram
Autologous Mesenchymal Stem Cells in Chronic Stroke
title Autologous Mesenchymal Stem Cells in Chronic Stroke
title_full Autologous Mesenchymal Stem Cells in Chronic Stroke
title_fullStr Autologous Mesenchymal Stem Cells in Chronic Stroke
title_full_unstemmed Autologous Mesenchymal Stem Cells in Chronic Stroke
title_short Autologous Mesenchymal Stem Cells in Chronic Stroke
title_sort autologous mesenchymal stem cells in chronic stroke
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343764/
https://www.ncbi.nlm.nih.gov/pubmed/22566987
http://dx.doi.org/10.1159/000333381
work_keys_str_mv AT bhasinashu autologousmesenchymalstemcellsinchronicstroke
AT srivastavamvpadma autologousmesenchymalstemcellsinchronicstroke
AT kumaranssenthil autologousmesenchymalstemcellsinchronicstroke
AT mohantysujata autologousmesenchymalstemcellsinchronicstroke
AT bhatiarohit autologousmesenchymalstemcellsinchronicstroke
AT bosesushmita autologousmesenchymalstemcellsinchronicstroke
AT gaikwadshailesh autologousmesenchymalstemcellsinchronicstroke
AT gargajay autologousmesenchymalstemcellsinchronicstroke
AT airanbalram autologousmesenchymalstemcellsinchronicstroke